Jazz Phase 3 of Zepzelca in second-line small cell lung cancer fails primary overall survival endpoint

 

Jazz Pharmaceuticals’ Phase 3 LAGOON trial of Zepzelca in second-line small cell lung cancer fails primary overall survival endpoint

• Company said LAGOON outcome does not affect Zepzelca’s existing first-line maintenance approval status
• Jazz Pharmaceuticals reaffirmed that its previously issued 2026 financial guidance remains unchanged despite the LAGOON trial results

https://finviz.com/stock?t=JAZZ&p=d